Eli Lilly and Company (NYSE:LLY) Shares Bought by Bluesphere Advisors LLC

Bluesphere Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,201 shares of the company’s stock after purchasing an additional 28 shares during the period. Bluesphere Advisors LLC’s holdings in Eli Lilly and Company were worth $992,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth $43,000. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $48,000. Highline Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 53.3% during the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock worth $57,000 after purchasing an additional 24 shares in the last quarter. Capital A Wealth Management LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $63,000. Finally, Bellwether Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $66,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $778.97 on Wednesday. The business’s fifty day moving average price is $781.26 and its 200 day moving average price is $800.21. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $738.26 billion, a P/E ratio of 63.38, a PEG ratio of 1.13 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company earned $2.58 EPS. Eli Lilly and Company’s revenue was up 45.2% on a year-over-year basis. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LLY shares. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Guggenheim restated a “buy” rating and issued a $936.00 price objective on shares of Eli Lilly and Company in a report on Friday, June 20th. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. Finally, Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.